Hyundai Bioscience Co Ltd
048410
Company Profile
Business description
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.
Contact
150 North-Ahyun Road
3rd Floor Academic Cooperation Building
Ehwa Women’s University
Seodaemun-gu
Seoul
KORT: +82 7070080114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,143.00 | 17.90 | 0.20% |
| CAC 40 | 8,263.87 | 355.13 | 4.49% |
| DAX 40 | 24,080.63 | 1,159.04 | 5.06% |
| Dow JONES (US) | 47,909.92 | 1,325.46 | 2.85% |
| FTSE 100 | 10,608.88 | 260.09 | 2.51% |
| HKSE | 25,710.89 | 182.13 | -0.70% |
| NASDAQ | 22,634.99 | 617.14 | 2.80% |
| Nikkei 225 | 55,959.42 | 349.00 | -0.62% |
| NZX 50 Index | 13,308.95 | 55.01 | 0.42% |
| S&P 500 | 6,782.81 | 165.96 | 2.51% |
| S&P/ASX 200 | 8,941.80 | 26.40 | 0.30% |
| SSE Composite Index | 3,968.33 | 26.67 | -0.67% |